RebeccaSuk(Suk)HeistMD

Oncology • Boston, MA

Hematologic Oncology, Thoracic Cancer

Associate Professor of Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Heist is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Heist's full profile

Already have an account?

Office
32 Fruit St
Yawkey 7B
Boston, MA 02114
Phone+1 617-724-4000

Fax+1 617-726-0453

Summary

Dr. Rebecca Heist is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from Harvard Medical School and has been in practice 18 years. She specializes in thoracic cancer and is experienced in the treatment of lung cancer, with a special focus on clinical trials of novel agents.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

Certifications & Licensure

MA State Medical License 2001 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2008 Apr 01
Completed
Phase 2
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2008 Apr 15
Completed
Phase 2
Safety, Pharmacokinetics (PK) of AKT and MEK Combination Start of enrollment: 2010 May 04
Completed
Phase 1
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2010 Jul 28
Completed
Phase 2
Cabozantinib in Advanced Solid Malignancies Start of enrollment: 2012 Jun 01
Completed
Phase 2
Sunitinib in Never-Smokers With Lung Adenocarcinoma Start of enrollment: 2013 May 01
Completed
Phase 2
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations Start of enrollment: 2013 Aug 01
Terminated
Phase 1
Relative Bioavailability of Pimasertib in Cancer Patients Start of enrollment: 2013 Nov 30
Completed
Phase 1
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) Start of enrollment: 2015 Jun 11
Completed
Phase 2
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor Start of enrollment: 2016 May 01
Completed
Phase 2
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors Start of enrollment: 2017 Feb 28
RECRUITING
PHASE1
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Start of enrollment: 2019 Jun 27
Terminated
Phase 1
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Start of enrollment: 2019 Sep 05
ACTIVE_NOT_RECRUITING
PHASE1
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Start of enrollment: 2021 Feb 24
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Start of enrollment: 2023 Mar 23
RECRUITING
PHASE1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3 citations
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
Jacob Sands, Myung-Ju Ahn, Aaron Lisberg, Byoung Chul Cho, George Blumenschein Jr
Journal of Clinical Oncology. 2025-04-01
3 citations
Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.
Catherine B Meador, Subba R Digumarthy, Beow Y Yeap, Yin P Hung, Mari Mino-Kenudson
Clinical Cancer Research. 2025-01-06
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.
Mrinal Gounder, Melissa Johnson, Rebecca S Heist, Geoffrey I Shapiro, Sophie Postel-Vinay
Nature Communications. 2025-01-06

Journal Articles

Oxford University Press Has Registered This DOI Pre-Publication
R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press

Lectures

c-Met expression and response to telisotuzumab vedotin (teliso-v) in patients with non-small cell lung cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Coronavirus Slowing Critical Cancer Research, ScreeningsDecember 21st, 2020
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted TumorsOctober 27th, 2019
Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLCJuly 4th, 2016
Join now to see all